BlossomHill Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-10.
BlossomHill Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 10, 2025. The filing reports $84.15M sold. Its industry group is Pharmaceuticals. It names JINGRONG JEAN CUI (Executive Officer, Director), YISHAN LI (Executive Officer, Director), GEORGE LEE (Director) (SEC Form D, December 10, 2025).
Sell to companies like BlossomHill Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns BlossomHill Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind BlossomHill Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when BlossomHill Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when BlossomHill Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch BlossomHill Therapeutics, Inc. →Get the full cited report on BlossomHill Therapeutics, Inc.
What the filing shows about BlossomHill Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BlossomHill Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on BlossomHill Therapeutics, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $84.15M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Jingrong Jean Cui is named as Executive Officer and Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
Yishan Li is named as Executive Officer and Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
George Lee is named as Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
Bihua Chen is named as Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
Carl Gordon is named as Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
Sundeep Agrawal is named as Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
Timothy Stubbs is named as Director on the Form D that BlossomHill Therapeutics, Inc. filed with the SEC on 10 December 2025, one of 7 people that filing names.
7 people named on the filing — 2 holding an executive role and 5 as directors only.
Named as of the 2025-12-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about BlossomHill Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BlossomHill Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BlossomHill Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist BlossomHill Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind BlossomHill Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for BlossomHill Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Diego
https://mentionfox.com/funding/blossomhill-therapeutics-inc-form-d-25000001